Abbott Laboratories (ABT) Short-Term Debt issuances (2009 - 2026)

Abbott Laboratories' Short-Term Debt issuances history runs 18 years deep, the most recent figure standing at $31.0 million for Q1 2026.

• In Q1 2026, Short-Term Debt issuances rose 186.11% year-over-year to $31.0 million; the TTM figure through Mar 2026 stood at -$48.0 million (down 433.33% YoY), while the FY2025 annual figure was -$115.0 million, down 15.0% from the prior year.
• Short-Term Debt issuances came in at $31.0 million for Q1 2026 at Abbott Laboratories, up from -$71.0 million in the prior quarter.
• In the past five years, Short-Term Debt issuances ranged from a high of $111.0 million in Q4 2023 to a low of -$127.0 million in Q1 2024.
• A 5-year average of -$6.8 million and a median of $8.0 million in 2022 frame the typical range for Short-Term Debt issuances.
• On a YoY basis, Short-Term Debt issuances climbed as much as 1010.0% in 2023 and fell as far as 625.0% in 2023.
• Abbott Laboratories' Short-Term Debt issuances stood at $10.0 million in 2022, then soared by 1010.0% to $111.0 million in 2023, then plunged by 76.58% to $26.0 million in 2024, then slumped by 373.08% to -$71.0 million in 2025, then soared by 143.66% to $31.0 million in 2026.
• According to Business Quant data, Short-Term Debt issuances over the past three periods registered $31.0 million, -$71.0 million, and $8.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison